Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Baxter
Dow
Boehringer Ingelheim
Express Scripts

Last Updated: August 13, 2022

Details for Patent: 6,469,012


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 6,469,012
Title: Pyrazolopyrimidinones for the treatment of impotence
Abstract:The use of a compound of formula (I) ##STR1## wherein R.sup.1 is H; C.sub.1 -C.sub.3 alkyl; C.sub.1 -C.sub.3 perfluoroalkyl; or C.sub.3 -C.sub.5 cycloalkyl; R.sup.2 is H; optionally substituted C.sub.1 -C.sub.6 alkyl; C.sub.1 -C.sub.3 perfluoroalkyl; or C.sub.3 -C.sub.6 cycloalkyl; R.sup.3 is optionally substituted C.sub.1 -C.sub.6 alkyl; C.sub.1 -C.sub.6 perfluoroalkyl; C.sub.3 -C.sub.5 cycloalkyl; C.sub.3 -C.sub.6 alkenyl; or C.sub.3 -C.sub.6 alkynyl; R.sup.4 is optionally substituted C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkanoyl, (hydroxy)C.sub.2 -C.sub.4 alkyl or (C.sub.2 -C.sub.3 alkoxy)C.sub.1 -C.sub.2 alkyl; CONR.sup.5 R.sup.6 ; CO.sub.2 R.sup.7 ; halo; NR.sup.5 R.sup.6 ; NHSO.sub.2 NR.sup.5 R.sup.6 ; NHSO.sub.2 R.sup.8 ; SO.sub.2 NR.sup.9 R.sup.10 ; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R.sup.5 and R.sup.6 are each independently H or C.sub.1 -C.sub.4 alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino, 4-N(R.sup.11)-piperazinyl or imidazolyl group; R.sup.7 is H or C.sub.1 -C.sub.4 alkyl; R.sup.8 is optionally substituted C.sub.1 -C.sub.3 alkyl; R.sup.9 and R.sup.10 together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino or 4-N(R.sup.12)-piperazinyl group; R.sup.11 is H; optionally substituted C.sub.1 -C.sub.3 alkyl; (hydroxy)C.sub.2 -C.sub.3 alkyl; or C.sub.1 -C.sub.4 alkanoyl; R.sup.12 is H; optionally substituted C.sub.1 -C.sub.6 alkyl; CONR.sup.13 R.sup.14 ; CSNR.sup.13 R.sup.14 ; or C(NH)NR.sup.13 R.sup.14 ; and R?13? and R.sup.14 are each independently H; C.sub.1 -C.sub.4 alkyl; or substituted C.sub.2 -C.sub.4 alkyl; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said male animal with said pharmaceutical composition or with said either entity.
Inventor(s): Ellis; Peter (Sandwich, GB), Terrett; Nicholas Kenneth (Sandwich, GB)
Assignee: Pfizer Inc (New York, NY)
Application Number:08/549,792
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,469,012
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 6,469,012

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,469,012

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9311920Jun 09, 1993
PCT Information
PCT FiledMay 13, 1994PCT Application Number:PCT/EP94/01580
PCT Publication Date:December 22, 1994PCT Publication Number: WO94/28902

International Family Members for US Patent 6,469,012

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 163852 See Plans and Pricing
Australia 676571 See Plans and Pricing
Australia 6797394 See Plans and Pricing
Canada 2163446 See Plans and Pricing
China 1071118 See Plans and Pricing
China 1124926 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Boehringer Ingelheim
Merck
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.